Precision Oncology
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
BridgeBio Discontinues Development of Gene Therapy for Congenital Adrenal Hyperplasia
The company said newly released Phase I/II study data for BBP-631 indicated the program did not merit further capital investment.
GenomOncology, Precipio Partner on Myeloid Test Reporting
GenomOncology's Pathology Workbench will be used as the clinical genomic reporting platform for Precipio's myeloid neoplasm test.
Digital Pathology Test Predicts NSCLC Patients' Response to AstraZeneca, Daiichi Sankyo's Dato-DXd
Premium
A quantitative continuous score identified patients with a TROP2 biomarker likely to respond to the antibody-drug conjugate, a study presented at WCLC showed.